Drug intelligence / Profile preview

miR-24 mimic

Development stage
Preclinical
Modality
Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratracheal, Intravenous, Local Injection
01

Overview

miR-24 mimic is a synthetic double-stranded RNA oligonucleotide designed to emulate the biological activity of endogenous microRNA-24 (miR-24). It functions as a microRNA replacement therapy by binding to the 3-untranslated regions (3-UTRs) of specific target mRNAs, leading to their degradation or translational repression. miR-24 is a pleiotropic regulator involved in various physiological and pathological processes, including apoptosis, inflammation, cell proliferation, and angiogenesis. Preclinical research has demonstrated that miR-24 mimics can attenuate ventilator-induced lung injury by targeting BOK, protect cardiomyocytes from ischemia-induced apoptosis by targeting Bim, and inhibit tumor growth in bladder and cervical cancers by modulating CARMA3 and PTEN/PI3K/AKT pathways, respectively. It is also being investigated for its potential to regulate inflammatory responses in atherosclerosis and infectious diseases like Staphylococcus aureus.

Other names
microRNA-24 mimicmicroRNA24 mimicmicroRNA 24 mimichsa-miR-24 mimichsa-miR24 mimichsa-miR 24 mimicmiR-24-3p mimicmiR24-3p mimicmiR 24-3p mimicmiR-24-1-5p mimicmiR24-1-5p mimicmiR 24-1-5p mimic
02

Targets

BOKBIMCARD10 (Caspase recruitment domain-containing protein 10)CHI3L1 (Chitinase-3-like protein 1)CDKN1B (Transmembrane emp24 domain-containing protein 7)KPNA4 (Karyopherin subunit alpha 3)MAPK14 (p38 mitogen-activated protein kinase alpha)PHD1 (Prolyl hydroxylase domain-containing protein 1)REG4

Beyond the preview

Go deeper on miR-24 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-24 mimic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call